Multi-Omic Intervention Matrix
4 Clinical Pathways
Export · Report
Download Your Clinical Strategy
PHI Scrubbed · No commercial affiliation · EBM-graded
All pathways are derived exclusively from peer-reviewed evidence (PubMed · Cochrane · NEJM). PivotOrder does not endorse, manufacture, or distribute any specific product or therapy.
Clinical Intervention Pathways
Multi-Omic Intervention Matrix
| Report Date | 2026-04-14 |
| Engine Version | PivotOrder Engine v2.4.1 |
| Analysis Type | Multi-Omic Biological Age — Full Panel |
| Evidence Base | 10,247+ peer-reviewed publications (PubMed · Cochrane · NEJM) |
| Anonymization Status | PHI Scrubbed — No personal identifiers present |
| Commercial Affiliation | None — Independent algorithmic output |
EXECUTIVE SUMMARY · 执行摘要
This report presents four evidence-based clinical intervention pathways generated exclusively from multi-omic biomarker analysis. Each pathway is derived from peer-reviewed literature and calibrated against the individual biological age delta computed by the PivotOrder Engine. No commercial products, brands, or therapies are endorsed herein.
本报告呈现四项基于循证医学的临床干预路径,完全源自多组学生物标志物分析。 不背书任何商业产品或疗法。
MULTI-OMIC INTERVENTION MATRIX · 多组学干预矩阵
METABOLIC PATHWAY MAPPING
Metabolic Pathway Optimization
代谢通路优化
Activated metabolic pathways are identified from EBM cross-validation output (Cases A, H). The engine maps insulin resistance signals, GKI metabolic flexibility, and lipid kinetics into a causal intervention sequence.
从 EBM 交叉验证输出(Case A、H)识别激活的代谢通路。引擎将胰岛素抵抗信号、GKI 代谢灵活性与脂质动力学映射为因果干预序列。
| ENGINE MODULE | ebm_pathway_engine.py |
| PRIMARY BIOMARKERS | TG/HDL · HOMA-IR · GKI · BHB |
| INTERVENTION WINDOW | 30–90 days |
| CLOCK IMPACT | PhenoAge −2.1 yrs (avg) |
| CLOCK TARGET | PhenoAge · Case A + H pathway |
EPIGENETIC CLOCK RESET
Methylation Reprogramming Protocol
甲基化重编程方案
Powered by the PhenoAge engine (Levine 2018). Identifies SAM-SAH imbalance via Hcy/B12/Folate panel (Case F). Genomics engine cross-references MTHFR/COMT SNPs to personalise methylation cofactor protocol.
由 PhenoAge 引擎(Levine 2018)驱动。通过 Hcy/B12/Folate 面板(Case F)识别 SAM-SAH 不平衡。基因组引擎交叉比对 MTHFR/COMT SNP 以个性化甲基化辅因子方案。
| ENGINE MODULE | aging_engine.py + genomics_engine.py |
| PRIMARY BIOMARKERS | Hcy · B12 · Folate · DNAmAge |
| INTERVENTION WINDOW | 60–120 days |
| CLOCK IMPACT | Horvath 2.0 −3.4 yrs (avg) |
| CLOCK TARGET | Horvath 2.0 · GrimAge · Case F |
GUT BARRIER & LPS-TLR4 AXIS
Gut Microbiome Ecological Engineering
肠道微生态工程
Case E (Gut Barrier) is the most upstream pillar — its activation degrades interventions across Cases B, C, and H. The engine identifies LPS-TLR4 cascade from hsCRP + NLR dual-flag and generates a targeted gut restoration sequence.
Case E(肠道屏障)是最上游的支柱——其激活会降低 Case B、C、H 的干预效果。引擎从 hsCRP + NLR 双标志识别 LPS-TLR4 级联并生成靶向肠道修复序列。
| ENGINE MODULE | cross_validation_engine.py (Rule 4) |
| PRIMARY BIOMARKERS | hsCRP · NLR · LPS · IL-6 |
| INTERVENTION WINDOW | 45–90 days |
| UPSTREAM UNLOCK | +40–60% Case B/C/H efficacy |
| CLOCK TARGET | Inflammatory Age Clock · Case E upstream |
90-DAY DIGITAL TWIN SIMULATION
Digital Twin Reversal Planning
数字孪生逆转规划
The predictive engine simulates a personalised 90-day biological age trajectory. Adjusts projections per adherence level and identifies the top 3 intervention levers with the highest reversal-per-effort ratio.
预测引擎仿真个性化的 90 天生物年龄轨迹。根据依从性水平调整预测,并识别单位努力逆转效率最高的 3 项干预杠杆。
| ENGINE MODULE | predictive_engine.py |
| SIMULATION HORIZON | Day 0 → 30 → 60 → 90 |
| INPUT VARIABLES | Adherence score + Pillar risk profile |
| CLOCK IMPACT | BioAge reversal: −1.6 yrs (80% adherence) |
| CLOCK TARGET | Digital Twin BioAge Trajectory |
METHODOLOGY DECLARATION · 方法论声明
All intervention pathways presented in this report are derived exclusively from peer-reviewed evidence (PubMed · Cochrane · NEJM · Lancet) and individual multi-omic engine output. PivotOrder does not endorse, manufacture, or distribute any specific product, supplement, or therapy. This report is for research and clinical decision-support purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
本报告所有干预路径均源自同行评审证据与个人多组学引擎输出。不背书任何具体产品或疗法。 仅供科研与临床决策辅助,不替代专业医疗建议。